Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-145 (nurulimab) in advanced melanoma
NCT03472027Phase 1Completed
- Sponsor
- BIOCAD
- Start
- Oct 2017
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nurulimab in melanoma (5 arms), sponsored by BIOCAD. Primary endpoint: Dose-Limiting Toxicities at 85 days. Started Oct 2017; status: completed.
02
Drugs
nurulimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03472027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03472027.